2405 Wesbrook Mall
About Zucara TherapeuticsZucara, a spin-off of The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI), is a company with a novel drug therapy to help prevent hypoglycemia in people with diabetes. It is advancing novel technology that is showing promise as a long-term therapeutic approach to prevent hypoglycemia in people with diabetes who are insulin-dependent.
CEO: Michael Midmer, MSc, MBA
CBO: Jonathon Jafari, MSc, MBA
CSO: Richard Liggins, PhD
Chair, Scientific Advisory Board: Michael Riddell, PhD
Director, Technology & Venture Development: Dominic Jaikaran, PhD, MBA
Please click here for Zucara's technology.
5 articles with Zucara Therapeutics
Zucara Therapeutics Secures US$3.9M from the Helmsley Charitable Trust to Advance Diabetes Drug Candidate to Clinical Trials
Zucara Therapeutics Inc., a diabetes life sciences company advancing the first once-daily therapeutic to prevent low blood glucose levels (hypoglycemia), has secured US$3.9 million in non-dilutive funding from The Leona M. and Harry B. Helmsley Charitable Trust.
Zucara recently defined its lead drug candidate, ZT-01, and this support will enable Zucara to conduct critical validation work and further advance ZT-01 through preclinical testing.
Zucara Therapeutics And The Centre For Drug Research And Development Complete Licensing Deal To Select Lead Therapeutic Drug Candidate